ACHL Projected Dividend Yield

ADS (Sponsored)/Achilles Therapeutics PLC ( NASDAQ : ACHL )

Achilles Therapeutics is a clinical stage immuno-oncology biopharmaceutical company developing T cell therapies to treat multiple types of solid tumors. Co.'s bioinformatic platform called PELEUS identifies mutations formed early in the development of a cancer that give rise to antigens. Co.'s manufacturing process, VELOS, uses the patient's T cells and blood-derived dendritic cells to create a Clonal Neoantigen Targeting T cell therapy that targets clonal neoantigens to eradicate the tumor. Co. also uses its Material Acquisition Platform network, which consists of a network of medical facilities, to collect tissue samples from other tumor types such as head and neck squamous cell carcinoma.

20 YEAR PERFORMANCE RESULTS